Metformin Hydrochloride is a biguanide indicated for type 2 diabetes mellitus. We supply it to US manufacturers of tablets, extended-release tablets, oral solution and fixed-dose combinations.
Data from PubChem (CID 14219) and FDA’s substance registry
CAS number
1115-70-4
Molecular formula
C4H12ClN5
Molecular weight
165.6g/mol
FDA UNII
IUPAC name
3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride
InChIKey
OETHQSJEHLVLGH-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline compound.
- Solubility
- Freely soluble in water, slightly soluble in alcohol, and practically insoluble in acetone and methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
A high-volume API where bulk density and particle size decide how it runs on your line. Since the 2020 recalls of extended-release tablets, NDMA data on the API is a standard request.
On the US market
- Reference product
- GlucophageNDA 020357
- Approved ANDAs
- 57 with a marketed product
- Approved forms and strengths
- Extended-release tablet 500 mg, 750 mg, 1 g
- Tablet 500 mg, 625 mg, 750 mg, 850 mg, 1 g
- Oral solution 500 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com